Trial
NCT02744287
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
Regeneron Pharmaceuticals
Collaborators
—
Condition
Metastatic Castration-resistant Prostate Cancer
Intervention
BPX-601
Why stopped
Due to a Dose Limiting Toxicity.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-23